1. Home
  2. NVRI vs MNMD Comparison

NVRI vs MNMD Comparison

Compare NVRI & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enviri Corporation

NVRI

Enviri Corporation

HOLD

Current Price

$17.80

Market Cap

996.0M

Sector

Miscellaneous

ML Signal

HOLD

Logo Mind Medicine (MindMed) Inc.

MNMD

Mind Medicine (MindMed) Inc.

HOLD

Current Price

$12.16

Market Cap

960.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVRI
MNMD
Founded
1853
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Pharmaceuticals and Biotechnology
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
996.0M
960.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NVRI
MNMD
Price
$17.80
$12.16
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$25.78
AVG Volume (30 Days)
2.3M
1.5M
Earning Date
11-10-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,244,061,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.42
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.72
$4.70
52 Week High
$18.74
$14.43

Technical Indicators

Market Signals
Indicator
NVRI
MNMD
Relative Strength Index (RSI) 71.78 50.93
Support Level $17.97 $12.19
Resistance Level $18.29 $13.02
Average True Range (ATR) 0.28 0.65
MACD -0.15 0.04
Stochastic Oscillator 0.56 32.60

Price Performance

Historical Comparison
NVRI
MNMD

About NVRI Enviri Corporation

Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Share on Social Networks: